All products are for laboratory research use only. Not for human consumption.
Immune · Immune Defense
The Immune Shield
RM 350
Fortify your sovereign shield. Thymosin Alpha-1 10 mg balances your body’s natural immune intelligence from the cell up.
For research use only. Not for human or veterinary consumption. This product is not a medicine and is not intended to diagnose, treat, cure or prevent any disease.
Overview
Thymosin Alpha-1 (Ta1) has accumulated the most comprehensive clinical evidence base of any peptide immunomodulator. FDA Orphan Drug designation. Approved as Zadaxin in 35+ countries for hepatitis B, hepatitis C, and immune reconstitution. Discovered in 1977 by Allan Goldstein, it activates dendritic cells, upregulates T cell function, and modulates cytokine signaling without causing autoimmune overstimulation.
Mechanism of action
Dendritic cell maturation and antigen presentation amplification
CD4+, CD8+, and NK cell differentiation and activation
IFN-gamma and IL-2 upregulation for immune response amplification
Key finding Thymosin Alpha-1 is the only immunomodulatory peptide with completed randomized controlled trials across four independent disease categories (hepatitis B, hepatitis C, cancer adjuvant therapy, and sepsis) — and the only peptide immunomodulator approved in 35+ countries with FDA Orphan Drug status.
Key research findings
Countries where Zadaxin is approved for hepatitis B, hepatitis C, and immune reconstitution indications
Zadaxin global prescribing informationThymosin Alpha-1 significantly increased HBV DNA clearance and HBeAg seroconversion in 255-patient Phase 3 RCT
Mutchnick MG et al. Hepatology, 1991Improved immune function and quality of life as adjuvant to chemotherapy — multiple oncology RCTs completed
Garaci E et al. Expert Opin Biol Ther, 2007Thymosin Alpha-1 improved 28-day mortality in severe sepsis — multiple clinical studies in China
Wu J et al. Crit Care Med, 2013Research areas
The most validated immunomodulator for cancer adjuvant therapy — improves chemotherapy outcomes and immune reconstitution.
FDA Orphan Drug status and Phase 3 data for hepatitis B and C — the deepest antiviral evidence of any peptide immunomodulator.
Reduced 28-day mortality in severe sepsis in clinical studies — unique critical illness immunomodulation data.
Thymosin Alpha-1 potentiates vaccine responses — established as a clinical vaccine adjuvant in multiple settings.
Safety profile
Thymosin Alpha-1 has the most comprehensive human safety database of any peptide immunomodulator — 40+ years and 35+ countries of clinical use.
Amplifies immune responses — note in autoimmune-prone research models
IFN-gamma and IL-2 elevation — note in cytokine-sensitive models
Enhanced antigen presentation — may amplify existing immune reactions
May potentiate immunosuppressive or immunostimulatory treatments
Molecular profile
Frequently asked questions
Zadaxin is approved in 35+ countries for: (1) Hepatitis B — as monotherapy and in combination; (2) Hepatitis C — in combination with interferon; (3) Adjuvant to chemotherapy in cancer treatment; (4) Immune reconstitution in immunocompromised patients. It carries FDA Orphan Drug designation in the United States.
Despite similar names, they are entirely different peptides with completely different mechanisms. Thymosin Alpha-1 (28 AA, molecular weight 3,108 Da) is an immunomodulator — it activates dendritic cells, T cells, and NK cells. Thymosin Beta-4 (43 AA, molecular weight 4,963 Da) is a tissue repair peptide that sequesters G-actin to enable cell migration. They do not share mechanism, receptor, or clinical application.
The pivotal 255-patient Phase 3 RCT (Mutchnick MG et al., Hepatology, 1991) demonstrated that Thymosin Alpha-1 significantly increased HBV DNA clearance and HBeAg seroconversion versus placebo over a 12-month treatment period. This trial formed the basis for regulatory approvals in multiple countries.
Sepsis causes immune paralysis — a state where T cells and dendritic cells become exhausted and unable to fight infection. Thymosin Alpha-1 reverses this immunoparalysis by restoring dendritic cell and T cell function. Chinese clinical studies showed improved 28-day survival in severe sepsis patients treated with Thymosin Alpha-1 versus standard care.
Unlike non-specific immune stimulants, Thymosin Alpha-1 restores immune balance rather than simply amplifying all immune activity. It upregulates regulatory T cells (Tregs) alongside effector T cells, maintaining immune homeostasis. In 40+ years of clinical use across millions of doses, autoimmune complications have not been a documented safety concern.
Yes. Multiple clinical studies have demonstrated that Thymosin Alpha-1 potentiates vaccine responses — particularly in elderly subjects and immunocompromised patients whose normal immune response to vaccination is diminished. This has been studied with influenza and hepatitis B vaccines.
References
